Health Insurance (Pathology Services Table) Amendment Regulations 2006 (No. 1)1 Select Legislative Instrument 2006 No. 87
I, PROFESSOR MARIE BASHIR, AC, CVO, Administrator of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973. Dated 26 April 2006 MARIE BASHIR Administrator By Her Excellency’s Command TONY ABBOTT Minister for Health and Ageing
1 Name of Regulations These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2006 (No. 1). 2 Commencement These Regulations commence on 1 May 2006. 3 Amendment of Health Insurance (Pathology Services Table) Regulations 2005 Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2005.
Schedule 1 Amendments (regulation 3) [1] Schedule 1, Part 2, subrule 1 (1), definition of recognised pathologist substitute recognised pathologist means: (a) a medical practitioner recognised as a specialist in pathology under subsection 3D (1) of the Act; or (b) a medical practitioner in relation to whom there is in force a determination under paragraph 3DB (4) (a) or subsection 3E (1) of the Act that the practitioner is recognised as a specialist in pathology. [2] Schedule 1, Part 2, subrule 4 (2) substitute (2) Rule 3 does not apply to a pathology service described in subrule (3) if: (a) under a request for a service, other than a request for a service described in paragraph (3) (a), no more than 6 tests are requested; and (b) the tests are performed within 6 months of the request; and (c) the account for the service is endorsed ‘Rule 3 Exemption’. (3) For subrule (2), the pathology services are: (a) estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy; and (b) quantitative estimation of lithium for a patient undergoing lithium therapy; and (c) a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy; and (d) a service described in item 65070 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient; and (e) a service described in any of items 66500 to 66515, in relation to methotrexate or leflunomide therapy of a patient; and (f) quantitative estimation of urea, creatinine and electrolytes in relation to: (i) cis-platinum or cyclosporin therapy of a patient; or (ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital; and (g) quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues; and (h) quantitative estimation of calcium, phosphate, magnesium, potassium, urea, creatinine and electrolytes for a cancer patient receiving bisphosphonate infusions. [3] Schedule 1, Part 2, rule 20 omit For item 66794: insert For item 73317: [4] Schedule 1, Part 2, subrule 25 (6) omit items 69445, 71079 and 73523 insert items 69445, 71079, 73314 and 73523 [5] Schedule 1, Part 3, item 65168 omit [6] Schedule 1, Part 3, items 65174 and 65200 omit [7] Schedule 1, Part 3, item 66794 omit [8] Schedule 1, Part 3, item 69486, column 2 substitute
A test for high risk human papillomaviruses (HPV) in a patient who: (a) within the 2 year period before the test, has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix; or
(b) within the 2 year period before the test, has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix; or
(c) is undergoing annual cytological review following treatment for HSIL of the cervix (Item is subject to rule 25)
[9] Schedule 1, Part 3, item 71146, column 2 after white cell count insert on the pheresis collection [10] Schedule 1, Part 3, after item 73305 insert in Group P7
73308
Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism — 1 or more tests
37.10
73311
Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item 73308 — 1 or more tests
37.10
73314
Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia (Item is subject to rule 25)
235.00
73317
Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)
37.10
73320
Detection of HLA-B27 by nucleic acid amplification
41.25
[11] Schedule 1, Part 4 omit
Factor V Leiden mutation
FVLM
65168, 65174
insert
Factor V Leiden mutation
FVLM
73308, 73311
[12] Schedule 1, Part 4 omit
Haemochromatosis
FEUP
66794
insert
Haemochromatosis
FEUP
73317
[13] Schedule 1, Part 4 omit
Prothrombin gene mutation
PGM
65168, 65174
insert
Prothrombin gene mutation
PGM
73308, 73311
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See www.frli.gov.au.
